60 Degrees Pharmaceuticals Announces Partnership with Runway Health to Provide International Travelers Direct Access to ARAKODA® for Malaria Prevention

Core Insights - 60 Degrees Pharmaceuticals, Inc. has announced a partnership with Runway Health to enhance access to ARAKODA (tafenoquine) for malaria prevention among international travelers [1][4] - ARAKODA is the only broad-spectrum, once-weekly prescription malaria prevention medication available in the U.S. market [2][9] - The partnership will commence on April 2, 2026, and aims to provide a personalized medical treatment plan for travelers [4] Company Overview - 60 Degrees Pharmaceuticals, Inc. specializes in developing new medicines for vector-borne diseases and received FDA approval for ARAKODA in 2018 [18] - The company is headquartered in Washington, D.C., and has a subsidiary in Australia, with ARAKODA commercially available in both countries [18] Product Information - ARAKODA (tafenoquine) is indicated for malaria prophylaxis in adults aged 18 and older and has been assessed for safety in multiple clinical trials [5][8] - The drug has a long terminal half-life of approximately 16 days, allowing for less frequent dosing [7] - ARAKODA is prescribed in a loading phase of 2 x 100 mg tablets once daily for three days before travel, followed by 2 x 100 mg tablets weekly during travel [7] Partnership Details - The collaboration with Runway Health will utilize a telehealth platform to facilitate online consultations and home delivery of ARAKODA before travel [2][4] - This partnership adds a consumer-focused approach to the marketing strategy of ARAKODA, targeting individuals planning to travel to malaria-endemic regions [9]